

**Analytical Profiles
of
Drug Substances**

Volume 11

Edited by
Klaus Florey

Analytical Profiles of Drug Substances

Volume 11

Edited by
Klaus Florey

The Squibb Institute for Medical Research
New Brunswick, New Jersey

Contributing Editors

| | |
|----------------------|--------------------|
| Gerald S. Brenner | Lee T. Grady |
| Glenn A. Brewer, Jr. | Hans-Georg Leemann |
| Lester Chafetz | Joseph Mollica |
| Nicholas DeAngelis | Milton D. Yudis |

*Compiled under the auspices of the
Pharmaceutical Analysis and Control Section
Academy of Pharmaceutical Sciences*



ACADEMIC PRESS 1982

A Subsidiary of Harcourt Brace Jovanovich, Publishers

New York London

Paris San Diego San Francisco São Paulo Sydney Tokyo Toronto

Academic Press Rapid Manuscript Reproduction

COPYRIGHT © 1982, BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED.

**NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.**

ACADEMIC PRESS, INC.

111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1 7DX

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 70-187259

ISBN 0-42-260811-9

PRINTED IN THE UNITED STATES OF AMERICA

82 83 84 85 9 8 7 6 5 4 3 2 1

AFFILIATIONS OF EDITORS, CONTRIBUTORS, AND REVIEWERS

- E. Abignente*, University of Naples, Naples, Italy
H. Y. Aboul-Enein, King Saud University, Riyadh, Saudi Arabia
A. A. Al-Badr, King Saud University, Riyadh, Saudi Arabia
I. A. Al-Meshal, King Saud University, Riyadh, Saudi Arabia
M. A. Al-Yahya, King Saud University, Riyadh, Saudi Arabia
S. L. Ali, Zentrallaboratorium Deutscher Apotheker e. V., Eschborn, Germany
N. W. Atwater, E. R. Squibb and Sons, Princeton, New Jersey
D. M. Baaske, American Critical Care, Chicago, Illinois
R. Bishara, Eli Lilly and Company, Indianapolis, Indiana
G. S. Brenner, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania
G. A. Brewer, Jr., The Squibb Institute for Medical Research, New Brunswick, New Jersey
P. de Caprariis, University of Naples, Naples, Italy
J. E. Carter, Ortho Pharmaceuticals, Somerville, New Jersey
L. Chafetz, Warner-Lambert Research Institute, Morris Plains, New Jersey
N. DeAngelis, Wyeth Laboratories, Philadelphia, Pennsylvania
W. DeWitte, Ciba-Geigy, Suffern, New York
H. A. El-Obeid, King Saud University, Riyadh, Saudi Arabia
A. A. Elazzouny, National Research Center, Dokki, Cairo, Egypt
J. Fairbrother, Stiefel Laboratories Ltd., Sligo, Ireland
K. Florey, The Squibb Institute for Medical Research, New Brunswick, New Jersey
S. A. Fusari, Parke-Davis, Inc., Detroit, Michigan
L. T. Grady, The United States Pharmacopeia, Rockville, Maryland
M. M. A. Hassan, King Saud University, Riyadh, Saudi Arabia
J. G. Hoogerheide, Schering-Plough Corporation, Bloomfield, New Jersey

- J. H. Johnson*, American Critical Care, Chicago, Illinois
H. Kadin, The Squibb Institute for Medical Research, New Brunswick, New Jersey
B. T. Kho, Ayerst Laboratories, Rouses Point, New York
F. Kreuzig, Biochemie GmbH, Kundl, Austria
H. G. Leemann, Sandoz, Basel, Switzerland
E. A. Lotfi, King Saud University, Riyadh, Saudi Arabia
M. E. Mohamed, King Saud University, Riyadh, Saudi Arabia
J. Mollica, Ciba-Geigy Corporation, Summit, New Jersey
F. J. Muhtadi, King Saud University, Riyadh, Saudi Arabia
V. D. Reif, Wyeth Laboratories, Philadelphia, Pennsylvania
B. C. Rudy, Mary Kay Cosmetics, Dallas, Texas
C. M. Shearer, Wyeth Laboratories, Philadelphia, Pennsylvania
D. H. Sieh, The Squibb Institute for Medical Research, New Brunswick, New Jersey
H. Stober, Ciba-Geigy, Suffern, New York
K. D. Thakker, The United States Pharmacopeia, Rockville, Maryland
T. D. Wilson, Sterling Winthrop Research Institute, Rensselaer, New York
B. E. Wyka, Schering-Plough Corporation, Bloomfield, New Jersey
M. D. Yudis, Schering-Plough Corporation, Bloomfield, New Jersey

PREFACE

It is now well over a decade that I perceived the need to supplement the official compendial standards of drug substances with a comprehensive review of pertinent physical, chemical, and analytical data and methods. Ten years ago the first volume of *Analytical Profiles of Drug Substances* was published under the auspices of the Pharmaceutical Analysis and Control Section of the APhA Academy of Pharmaceutical Sciences. That we were able to publish one volume per year is a tribute to the diligence of the editors to solicit monographs and even more so to the enthusiastic response of our authors, an international group associated with pharmaceutical firms, academic institutions, and compendial authorities. I would like to express my sincere gratitude to them for making this venture possible.

I am pleased to report that five years ago a companion series entitled *Pharmacological and Biochemical Properties of Drug Substances* was initiated by Morton E. Goldberg under the auspices of the section on Pharmacology and Toxicology, APhA Academy of Pharmaceutical Sciences. So far, three volumes have been published.

Over the years, we have had queries concerning our publication policy. Our goal is to cover all drug substances of medical value and, therefore, we have welcomed any monographs of interest to an individual contributor. We also have endeavored to solicit profiles of the most useful and used medicines, but many in this category still need to be profiled.

Starting with this, the eleventh volume, we shall also supplement previously published profiles with new data as we can find volunteers to write such supplements. In this volume, five of the original profiles in Volume 1 have been updated.

The goal to cover and update all drug substances of medical value with comprehensive monographs is still a distant one. I estimate that only about a quarter of such compounds have been profiled so far. We would very much like to accelerate

the rate of publication and hope that even more authors can be encouraged to write profiles. All those who have found these profiles useful are requested to contribute monographs of their own. We, the editors, stand ready to receive such contributions.

Klaus Florey

CONTENTS

| | |
|--|---------|
| <i>Affiliations of Editors, Contributors, and Reviewers</i> | viii |
| <i>Preface</i> | ix |
| Aminophylline | 1 |
| <i>Katlas D. Thakker and Lee T. Grady</i> | |
| Ascorbic Acid | 45 |
| <i>Ibrahim A. Al-Meshal and Mahmoud M.A. Hassan</i> | |
| Captopril | 79 |
| <i>Harold Kadin</i> | |
| Cefotaxime | 139 |
| <i>Farid J. Muhtadi and Mahmoud M.A. Hassan</i> | |
| Cefoxitin, Sodium | 169 |
| <i>Gerald S. Brenner</i> | |
| Clofibrate | 197 |
| <i>Mahmoud M.A. Hassan and Aida A. Elazzouny</i> | |
| Clotrimazole | 225 |
| <i>John G. Hoogerheide and Bruce E. Wyka</i> | |
| Dopamine Hydrochloride | 257 |
| <i>James E. Carter, John H. Johnson, and David M. Baaske</i> | |
| Ergonovine Maleate | 273 |
| <i>Van D. Retf</i> | |

| | |
|--|-----|
| Flufenamic Acid | 313 |
| <i>Enrico Abignente and Paolo de Capraris</i> | |
| Hexestrol | 347 |
| <i>Hassan Y. Aboul-Enein, Essam A. Lotfi, and Mohamed E. Mohamed</i> | |
| Mestranol | 375 |
| <i>Humeida A. El-Obeid and Abdullah A. Al-Badr</i> | |
| Noscapine | 407 |
| <i>Mohammed A. Al-Yahya and Mahmoud M.A. Hassan</i> | |
| Penicillin-G Benzathine | 463 |
| <i>Franz Kreuzig</i> | |
| Phenylbutazone | 483 |
| <i>Syed Laik Ali</i> | |
| Sulfadiazine | 523 |
| <i>Henry Stober and Wayne DeWitte</i> | |

PROFILE SUPPLEMENTS

| | |
|---------------------------|-----|
| Levarterenol Bitartrate | 555 |
| <i>Terry D. Wilson</i> | |
| Meprobamate | 587 |
| <i>Charles M. Shearer</i> | |
| Triamcinolone | 593 |
| <i>David H. Sieh</i> | |
| Triamcinolone Acetonide | 615 |
| <i>David H. Sieh</i> | |
| Triamcinolone Diacetate | 651 |
| <i>David H. Sieh</i> | |

AMINOPHYLLINE

Kailas D. Thakker and Lee T. Grady

| | |
|--|----|
| 1. Description | 2 |
| 1.1 Nomenclature | 2 |
| 1.2 Formula, Molecular Weight, and Composition | 2 |
| 1.3 Appearance, Color, and Odor | 2 |
| 2. Physical Properties | 3 |
| 2.1 Spectral | 3 |
| 2.2 Other Properties | 3 |
| 3. Methods of Preparation | 9 |
| 4. Stability-Degradation | 9 |
| 4.1 Stability in Solution | 9 |
| 4.2 Stability in Solid State | 9 |
| 5. Methods of Analysis | 10 |
| 5.1 Identification Tests | 10 |
| 5.2 Gravimetric Methods | 11 |
| 5.3 Titrimetric Methods | 11 |
| 5.4 Spectroscopic Methods | 13 |
| 5.5 Chromatographic Methods | 13 |
| 5.6 Immunoassays | 26 |
| 6. Metabolism | 31 |
| 7. Biopharmaceutics and Pharmacokinetics | 31 |
| 8. Toxicity | 33 |
| 9. References | 34 |

1. Description

1.1 Nomenclature

1.11 Chemical Name

Aminophylline is chemically known as 1H-purine-2,6-dione,3,7-dihydro-1,3-dimethyl-, compound with 1,2-ethanediamine (2:1).¹


1.12 Adopted Names

Aminophylline was also known as theophylline ethylenediamine and euphylline.¹

1.13 Trade Names

Aminophylline is known as carena; inophylline; metaphylline; theophyldine; aminocardol; amnophylline; cardiocilina; cardophyllin; phylcardin; tefamin; cardiomin; grifomin; minaphil; peterphylline; stenovasan; thedrox; diophylline; genophylline; phyllindon and theolamine.¹

1.2 Formula, Molecular Weight, and Composition:



Anhydrous: $C_{16}H_{24}N_{10}O_4$ 420.44

Dihydrate: $C_{16}H_{28}N_{10}O_6$ 456.44

Theophylline 85-87%

Ethylenediamine 12-15%

1.3 Appearance, Color and Odor

Aminophylline is available in the anhydrous form or as the dihydrate. The dihydrate occurs as white or slightly yellowish granules or powder. It has a faint ammoniacal odor and a bitter taste.¹

2. Physical Properties

2.1 Spectral

2.1.1 Infrared

The infrared spectrum of aminophylline in mineral oil mull, obtained on a Beckman 4250 spectrophotometer, is shown in Figure 1.² It is generally consistent with the reported infrared spectrum of theophylline.^{3,4} The stretches for -NH_2 in ethylenediamine and -NH in theophylline appear as a broad band (combined with the mineral oil signal) in the region of $3.0\text{--}4.0\text{ }\mu\text{m}$. Other signals are in the same vicinity as those for theophylline. The fingerprint region beyond $8.5\text{ }\mu\text{m}$ is distinctive and can be used for identification.

2.1.2 Ultraviolet

Spectral characteristics of aminophylline solutions in the ultraviolet region were reported by Andrade and Inacio.⁵ Absorption maxima occurred at $243\text{--}5\text{ nm}$ [$E_{1\%}^{1\text{cm}} = 170$] and at $273\text{--}5$ [$E_{1\%}^{1\text{cm}} = 500$] in pH 9.5 borate buffer.

Figure 2 shows the ultraviolet spectrum of aminophylline in water obtained on a Beckman 5260 recording spectrophotometer.

2.1.3 Nuclear Magnetic Resonance

2.1.3.1 Proton NMR

An 80 MHz proton magnetic resonance spectrum of aminophylline in d_6 -dimethyl sulfoxide, obtained on a Varian FT-80A,⁶ containing tetramethylsilane as an internal reference, is shown in Figure 3. It is similar to the reported (60 MHz) proton NMR of theophylline.³ The assignments, based on assignments of theophylline protons, are shown in Table I.

2.1.3.2 Carbon-13 NMR

The 20 MHz proton-noise decoupled ^{13}C spectrum of aminophylline in d_6 -dimethyl sulfoxide, obtained on a Varian FT-80A is shown in Figure 4.⁶ The assignments are shown in Table II. These are based on assignments of dimethyluracil and 1-methylhypoxanthine.⁷




Fig. 1. IR Spectrum of Aminophylline




Fig. 2. UV Spectrum of Aminophylline




Fig. 3. ^1H NMR of Aminophylline




Fig. 4. ^{13}C NMR of Aminophylline

Table I

| <u>Proton Assignment</u> | <u>Proton Position (see structure)</u> | <u>Chemical Shift (ppm)</u> |
|--------------------------|--|-----------------------------|
| -CH ₂ - | 10,11 | 2.75 |
| -N-CH ₃ - | 1 | 3.23 |
| N-CH ₂ - | 3 | 3.42 |
| N-H ^a | 7 | 5.67 |
| C-H | 8 | 7.71 |

^aIntensity of signal is proportional to the concentration.
This proton may be delocalized in the ring.

Table II

| <u>Carbon Assignment</u> | <u>Carbon Position (see structure)</u> | <u>Chemical Shift</u> |
|--------------------------|--|-----------------------|
| N-CH ₃ | 1 | 29.7 [•] |
| N-CH ₃ | 3 | 27.5 |
| C=C | 5 | 109.6 |
| C=C | 4 | 148.5 |
| N-C-N | 8 | 142.7 |
| -C=O | 2 | 151.4 |
| N-C=O-N | 6 | 155.6 |

-CH₂ on ethylenediamine is buried in the solvent signal as shown in Figure 4.

2.2 Other Properties

2.21 Differential Scanning Calorimetry and Melting Point

The thermogram of aminophylline² shows two endothermic transitions, one at 120° and another at 272°C. The first transition reflects the melting point of aminophylline; the second transition reflects the melting point of theophylline. Theophylline is known to sublime on melting.²

2.22 Solubility

Aminophylline is soluble in water